At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 58 enrolled
Drug / intervention
Blood Samplingprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™
In Brief
A Phase 4 clinical trial evaluating Blood Sampling for Tetanus and 6 related conditions. Completed, enrolled 58 participants across 4 sites in 2 countries.
Detailed Summary
The aim of this study is to assess antibody persistence in infants who received three doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) or Infanrix-IPV/Hib™ (DTPa-IPV/Hib) at 3, 5 and 11 months of age in study NCT00307034.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTetanus, Poliomyelitis, Haemophilus Influenzae Type b, Acellular Pertussis, Diphtheria, Hepatitis B, Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines
CountriesNorway, Sweden
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartMay 2011
Primary CompletionJul 2011
TodayJul 2026
First PostedMay 24, 2011
Enrollment StartMay 30, 2011
Primary CompletionJul 15, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.1 years ago
Interventions
Blood Samplingprocedure
A blood sample will be taken at 5 years of age, after vaccination in the primary study.